RSS

ABSSSI

The Food and Drug Administration (FDA) has granted fast track designation for Motif Bio’ iclaprim intravenous (IV) drug to treat acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP) more

News